At the 71st World Health Assembly, KEI will deliver the following intervention regarding the Global Strategy and Plan of Action on Public Health, Innovation, and Intellectual Property: 11.6 Global strategy and plan of action on public health, innovation and intellectual… Continue Reading
21 May 2018 Knowledge Ecology International (KEI) intends to deliver the following statement on Addressing the global shortage of, and access to, medicines and vaccines. 11.5 Addressing the global shortage of, and access to, medicines and vaccines Documents A71/12 and… Continue Reading
On May 18, 2018 KEI requested that the Department of Health and Human Services (HHS) investigate the failure to disclose National Institutes of Health (NIH) funding in four patents on Vizamyl (INN flutemetamol F 18), which is used to evaluate… Continue Reading
On Wednesday, 23 May 2018, Knowledge Ecology International and Stichting Health Action International (HAI) are convening a panel discussion on WHO’s Roadmap on Access to Medicines and Vaccines from 12h30 to 14h30 in Espace Henry Dunant at the Red Cross… Continue Reading
On April 19, 2018, KEI filed a lawsuit against the National Institutes of Health (NIH) to block or invalidate an exclusive license of patents on a new chimeric antigen receptor T-cell (CAR T) therapy to Gilead Sciences. A copy of… Continue Reading
FOR IMMEDIATE RELEASE April 5, 2018 kim.treanor@keionline.org (202)-332-2670 Six organizations are asking Department of Health and Human Services Secretary Alex Azar to take actions to lower the price of eteplirsen, a drug sold under the brand name Exondys 51, to… Continue Reading
On March 21, 2018, KEI asked the NIH to investigate the failure of James Griffin, the Dana-Farber Cancer Institute and Novartis to disclose millions of dollars in NIH grants related to two patents for the leukemia drug midostaurin, marketed by… Continue Reading
Update: In a letter dated March 28, 2018, Robert Firestone wrote to the NIH on behalf of Penn, stating that the NIH grants were infrastructure grants that did not give the NIH rights in the inventions. 2018-03-28-Penn-Response-juxtapid-Rader On March 19,… Continue Reading
1994. The 1994 NIH Report on CRADAs and the Reasonable Pricing Clause 1994. September 8. James Love. Pricing of Drugs Developed with Public Funds. Comments Presented to the Second NIH CRADA Forum. 1995. April 11. NIH Notice Rescinding the Reasonable… Continue Reading